Wenbin Ouyang

Wenbin Ouyang

Auto-generated profile, based on publicly available information

Wenbin Ouyang

Department of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 100037 Beijing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in Science Advances
Verified
Journal Article
Open access
WLWenshuai Liu
Wenshuai Liu
RGRui Gao
Rui Gao
CYChunfang Yang
Chunfang Yang
ZFZujian Feng
Zujian Feng
WOWenbin Ou-Yang
Wenbin Ou-Yang
WWWei wei Wang
Wei wei Wang
The treatment of difficult-to-heal wounds remains a substantial clinical challenge due to deteriorative tissue microenvironment including the loss of extracellular matrix (ECM), excessive inflammation, impaired angiogenesis, and bacterial infection. Inspired by the chemical components, fibrous structure, and biological function of natural ECM, antibacterial and tissue environment–responsive glycopeptide hybrid hydrogel was developed for chronic wound healing. The hydrogel can facilitate the cell proliferation and macrophage polarization to M2 phenotype, and show potent antibacterial efficacy against both Gram-negative and Gram-positive bacteria. Significantly, the glycopeptide hydrogel accelerated the reconstruction of methicillin-resistant Staphylococcus aureus (MRSA)–infected full-thickness diabetic and scalding skin by orchestrating a pro-regenerative response indicated by abundant M2-type macrophages, attenuated inflammation, and promoted angiogenesis. Collectively, ECM-mimetic and immunomodulatory glycopeptide hydrogel is a promising multifunctional dressing to reshape the damaged tissue environment without additional drugs, exogenous cytokines, or cells, providing an effective strategy for the repair and regeneration of chronic cutaneous wounds.

12 January 2022 in Regenerative Biomaterials
Verified
Journal Article
Open access
PDF file
YWYaping Wang
Yaping Wang
ZFZujian Feng
Zujian Feng
XLXiang Liu
Xiang Liu
CYChunfang Yang
Chunfang Yang
RGRui Gao
Rui Gao
WWWei wei Wang
Wei wei Wang
Titanium alloy has been widely used in orthopedic surgeries as bone defect filling. However, the regeneration of high-quality new bones is limited due to the pro-inflammatory microenvironment around implants, resulting in a high occurrence rate of implant loosening or failure in osteological therapy. In this study, extracellular matrix-mimetic polysaccharide hydrogel co-delivering BMP-2 and interleukin (IL)-4 was composited with 3D printed titanium alloy to promote the osseointegration and regulate macrophage response to create a pro-healing microenvironment in bone defect. Notably, it is discovered from the bioinformatics data that IL-4 and BMP-2 could affect each other through multiple signal pathways to achieve a synergistic effect toward osteogenesis. The composite scaffold significantly promoted the osteoblast differentiation and proliferation of human bone marrow mesenchyme stem cells (hBMSCs). The repair of large-scale femur defect in rat indicated that the dual-cytokine-delivered composite scaffold could manipulate a lower inflammatory level in situ by polarizing macrophages to M2 phenotype, resulting in superior efficacy of mature new bone regeneration over the treatment of native titanium alloy or that with an individual cytokine. Collectively, this work highlights the importance of M2-type macrophages-enriched immune-environment in bone healing. The biomimetic hydrogel–metal implant composite is a versatile and advanced scaffold for accelerating in vivo bone regeneration, holding great promise in treating orthopedic diseases.

27 April 2020 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
PDF file
PLPing Li
Ping Li
FFFang Fang
Fang Fang
XQXu Qiu
Xu Qiu
NXNan Xu
Nan Xu
YWYan Wang
Yan Wang
XPXiang-Bin Pan
Xiang-Bin Pan
Background. To evaluate the feasibility of using a single device to close multiple atrial septal defects (ASDs) under the guidance of transthoracic echocardiography (TTE) and with the aid of three-dimensional (3D) printing models. Methods. Sixty-two patients with multiple ASDs were retrospectively analyzed. Thirty of these patients underwent TTE-guided closure (3D printing and TTE group) after a simulation of occlusion in 3D printing models. The remaining 32 patients underwent ASD closure under fluoroscopic guidance (conventional group). Closure status was assessed immediately and at 6 months after device closure. Results. Successful transcatheter closure with a single device was achieved in 26 patients in the 3D printing and TTE group and 27 patients in the conventional group. Gender, age [18.8 ± 15.9 (3–51) years in the 3D printing and TTE group; 14.0 ± 11.6 (3–50) years in the conventional group], mean maximum distance between defects, prevalence of 3 atrial defects and large defect distance (defined as distance ≥7 mm), and occluder size used were similarly distributed between groups. However, the 3D printing and TTE group had lower frequency of occluder replacement (3.8% vs 59.3%, p<0.0001), prevalence of mild residual shunts (defined as <5 mm) immediately (19.2% vs 44.4%, p<0.05) and at 6 months (7.7% vs 29.6%, p<0.05) after the procedure, and cost (32960.8 ± 2018.7 CNY vs 41019.9 ± 13758.2 CNY, p<0.01). Conclusion. The combination of the 3D printing technology and ultrasound-guided interventional procedure provides a reliable new therapeutic approach for multiple ASDs, especially for challenging cases with large defect distance.

15 November 2022 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
ZLZefu Li
Zefu Li
PKPengxu Kong
Pengxu Kong
BWBin Wen
Bin Wen
SWShouzheng Wang
Shouzheng Wang
FZFengwen Zhang
Fengwen Zhang
XPXiangbin Pan
Xiangbin Pan
Background: Mitral regurgitation (MR) is one of the most prevalent valvular diseases. Degenerated MR-induced volume overload leads to left atrial enlargement and eventually, atrial fibrillation (AF). AF has a negative effect on patient prognosis despite recent advances in minimal invasive transcatheter devices for valve surgery. However, more effective strategies aimed at precisely treating from pathophysiology and genetic perspective are scarce. Methods: The gene expression datasets, GSE109744 and GSE79768, were obtained from the Gene Expression Omnibus database and analyzed to identify the differentially expressed genes (DEGs) in patients with mitral value prolapse (MVP) and AF. Subsequently, we predicted the extensive miRNA targets, and the protein-protein interaction (PPI) and miRNA-target gene regulatory networks were established. Functional enrichment analyses were performed for the DEGs. In addition, the co-expressed DEGs coupled with their predicted miRNAs and disease phenotypes involved in MVP and AF were assessed. Finally, the immune infiltration in both datasets was examined. Results: A total of 491 and 180 DEGs were identified in the mitral valve and left atrial specimens, respectively. From these, 11 integrated co-expressed DEGs were identified, namely, PRG4, GPR34, RELN, CA3, IL1B, EPHA3, CHGB, TCEAL2, B3GALT2, ASB11, and CRISPLD1. The enriched Gene Ontology terms and KEGG pathways associated with the DEGs were determined, and the top 10 hub genes and top 3 gene clusters were selected from the PPI network. A prediction of target miRNAs was performed based on the co-expressed DEGs. The enrichment of the co-expressed DEGs suggested that immune and inflammatory responses might be involved in the disease development through multiple immune related pathways, including the interaction of cytokines and chemokines. Notably, this result was consistent with the immune infiltration analysis since the proportions of naïve B cells and memory B cells were significantly different in MVP and AF tissues compared to normal tissues. Conclusions: MR and AF are related, and 11 co-expressed DEGs were found to be significantly associated with MVP with AF, and indeed, these may represent novel biomarkers. Several immune cells were found to contribute to the process of MVP and AF via diverse mechanisms, in particular, antigen-presenting cells.

11 February 2025 in Open Heart
Verified
Journal Article
Open access
HJHong Jiang
Hong Jiang
ZLZeye Liu
Zeye Liu
PWPeijian Wei
Peijian Wei
FZFengwen Zhang
Fengwen Zhang
SWShouzheng Wang
Shouzheng Wang
XPXiangbin Pan
Xiangbin Pan
Background: Over the past three decades, significant disparities in the global burden of cardiovascular disease (CVD) have been observed, particularly CVD attributed to secondhand smoke. However, a comprehensive understanding of global trends and their interaction with secondhand smoke remains inadequate. Methods: Using Global Burden of Disease data (1990–2019), an age-period-cohort analysis examined temporal trends in CVD mortality among secondhand smoke-exposed populations, considering age, period and cohort interactions. Results: Over the 30-year period, the global number of CVD deaths attributed to secondhand smoke increased substantially, from 432.6 thousand in 1990 (95% UI: 357.4–508.3) to 598.5 thousand in 2019 (95% UI: 489.7–713.5), representing a 38.4% increase (95% UI: 26.8%–49.5%). In 2019, CVD accounted for 45.9% of all deaths attributable to secondhand smoke among both sexes globally. Among these CVD deaths, ischaemic heart disease predominated, accounting for 66.4% of cases, compared with stroke. The distribution by sex revealed a slightly lower percentage of males (46.5%) than females (53.5%). Age-period-cohort models show overall global decline in CVD mortality due to secondhand smoke over 30 years, with regional, sex and subtype variations. Notably, a higher Sociodemographic Index (SDI) correlated with a greater reduction in mortality, exhibiting a significant 39.1% decrease in high SDI areas (95% UI: 35.6%–42.3%), in stark contrast to the minimal change observed in low SDI areas (0.1%, 95% UI: −52.4%–62.2%). Conclusions: This study highlights the importance of considering secondhand smoke as a modifiable CVD risk. Further research is needed to understand disparities in CVD burden across development levels, sexes and subtypes.

1 July 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
JMJianrui Ma
Jianrui Ma
CWCheng Wang
Cheng Wang
SWShouzheng Wang
Shouzheng Wang
FFFang Fang
Fang Fang
FZFengwen Zhang
Fengwen Zhang
CWChuangshi Wang
Chuangshi Wang
Background: The standard transcatheter edge‐to‐edge repair (TEER) procedure is commonly performed under the coguidance of both transesophageal echocardiography (TEE) and fluoroscopy. Our group has successfully simplified the procedural methodology by performing the TEER procedure under sole TEE guidance. The Echo‐CLIP study is designed to evaluate the efficacy, safety, and economic cost of the novel guidance strategy compared with the conventional one. Methods: The ECHO‐CLIP study contains an open‐label, prospective, multicenter, noninferiority, randomized clinical trial aiming to compare the outcomes of TEER procedure under the sole TEE guidance with coguidance of TEE and fluoroscopy in treating patients with mitral regurgitation ≥3+. A total of 200 patients will be enrolled and randomized in a 1:1 ratio to the 2 groups. The primary outcome is the success rates at 30 days after device implantation. The secondary outcomes include multiple indicators in terms of survival, adverse events, quality of life, physical functional capacity, hemodynamics, and economic costs at 30 days, 3 months, and 1 year. The ECHO‐CLIP study also contains an additional single‐arm cohort to evaluate outcomes of solely TEE‐guided TEER in those patients contraindicated to radiation. Conclusion: The ECHO‐CLIP study will determine whether the outcomes of TEER under sole TEE guidance are noninferior to those under conventional coguidance of TEE and fluoroscopy. The study will offer supportive clinical evidence of this novel procedural methodology and extend TEER application. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT06684171.